search
Back to results

Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression

Primary Purpose

Bipolar Depression

Status
Not yet recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Exercise Session
Ibuprofen 800 mg
Rest
Placebo
Sponsored by
Laureate Institute for Brain Research, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Bipolar Depression

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Provision of signed and dated informed consent form Has an established residence and phone Agrees to and is eligible for behavioral testing, magnetic resonance imaging, and blood draws. Stated willingness to comply with all study procedures and lifestyle considerations (see Section 5.3, Lifestyle Considerations) and availability for the duration of the study Males and females; Age 18-55 years DSM-V diagnosis of bipolar disorder Has a current major depressive episode Depression at enrollment of sufficient severity to score > 11 on the QIDS Be stably medicated for at least 4 weeks (a non-medicated subject may be included in the study if judged to be appropriate in the medical/psychiatric opinion of the investigator) BMI between 18.5 and 35 Exclusion Criteria: Diagnosis of any other major psychiatric disorder such as schizoaffective disorder, schizophrenia, or current psychotic depression A history of bipolar disorder with rapid cycling Concurrent manic symptoms of sufficient severity to pose a substantial risk of the development of a manic episode (>19 on the YMRS) Current drug or alcohol or substance use disorder moderate or severe, except nicotine (within 6 months for severe use disorder; 2 months for moderate use disorder) Volunteers currently receiving more than 4 mood-relevant psychotropic medications in a daily regimen (since this may signify a more brittle or complex clinical state) Taking any of the following medications: medications with significant interactions with ibuprofen; immune-modulating medications (e.g. oral steroids); regular use of NSAIDs (> 3 times per week) Current or prior cardiac disease, cardiac arrhythmia (e.g. supraventricular tachycardia, atrial fibrillation, ventricular fibrillation), or history of cardiac ablation therapy Unstable medical condition, including significant respiratory disease (e.g., asthma, reactive airway disease (i.e., exercise induced asthma), or chronic obstructive pulmonary disease (COPD)), liver disease, hypothyroidism (i.e., condition not adequately stabilized for 3 months), or other conditions likely to require hospitalization or with a life expectancy of < 6 months (e.g., cancer). History of claustrophobia that would prevent participation in imaging scans Actively suicidal, as defined by expressive ideation with a plan and intent for suicide or developing suicidal ideation that requires immediate medical or treatment intervention or a suicide attempt within the previous six months Participants who endorse a history of moderate to severe traumatic brain injury (>30 min. loss of consciousness or >24 hours posttraumatic amnesia) or other neurocognitive disorder with evidence of neurological deficits Inadequate understanding of English Currently pregnant or breast-feeding; fecund women not using adequate contraceptive methods; plan to become pregnant within 12 months Metal in the body (e.g. history of working as a sheet metal worker) or pacemaker which is a contra-indication to magnetic resonance imaging Has epilepsy, a neuromuscular disorder, or tardive dyskinesia Has a chronic infectious illness Requires immediate hospitalization for psychiatric disorder Requires medications for a general medical condition that contraindicate any study medication Receiving or have received during the index episode vagus nerve stimulation, electroconvulsive therapy, transcranial magnetic stimulation, or other somatic treatments Allergy to, or other medical contraindication to ibuprofen (e.g. stomach ulcers) Symptoms of myalgic encephalomyelitis/chronic fatigue syndrome or "long-COVID". Current use of medications or dietary supplements for weight or appetite control, whether prescribed or not Ulcerative colitis, Crohn's disease or other autoimmune disorder (except treated hypothyroidism) Activity restrictions that limit the subject's ability to engage in intense physical activity Use of beta-blockers, calcium channel inhibitors, or other heart-modulating medications (e.g., amiodarone) Clinically significant abnormality on EKG Hypertension, hepatitis, renal dysfunction, and/or anemia of sufficient severity to pose a risk to the participant Moderate or heavy smoker based on Fagerstrom Resting heart rate >100 beats per minute, systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg Clinically significant screening laboratory abnormalities not covered above Any reason not listed herein that would make participation in the study hazardous

Sites / Locations

  • Laureate Institute for Brain Research

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Session 1

Session 2

Session 3

Session 4

Arm Description

Exercise (30 min on bicycle ergometer at 60% peak power output) and a single oral dose 800mg of ibuprofen

Exercise (30 min on bicycle ergometer at 60% peak power output) and matching placebo

30 minutes rest (sitting in chair) and a single oral dose 800mg of ibuprofen

30 minutes rest (sitting in chair) and matching placebo

Outcomes

Primary Outcome Measures

Depressive Symptoms
Quick Inventory of Depressive Symptomatology (QIDS)
Inflammation
Serum concentrations of interleukin 6 (IL-6)

Secondary Outcome Measures

Neural Response to Reward
Percent Signal Change in Ventral Striatum During Monetary Incentive Delay (MID) task
Brain Volume
Gray Matter Volume of the Hippocampus
Inflammation
Serum concentrations of tumor necrosis factor (TNF)
Inflammation
Serum concentrations of interleukin 10 (IL-10)
Depressive Symptoms
Score on the Montgomery-Asberg Depression Rating Scale (MADRS)
Anhedonia
Score on the Snaith-Hamilton Pleasure Scale (SHAPS)
Anxiety
Score on the Hamilton Anxiety Scale (Clinician-Administered Version - SIGH-A)

Full Information

First Posted
October 12, 2023
Last Updated
October 12, 2023
Sponsor
Laureate Institute for Brain Research, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT06088732
Brief Title
Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression
Official Title
Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
December 1, 2023 (Anticipated)
Primary Completion Date
December 31, 2025 (Anticipated)
Study Completion Date
December 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Laureate Institute for Brain Research, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a 2x2, within-subjects, cross-over trial to test the anti-depressant effects of acute exercise in 20 participants with bipolar depression. Participants will complete four experimental sessions, two with an exercise challenge and two with a resting control condition in a counterbalanced order. Participants will receive either 800mg of ibuprofen or placebo before exercise or rest in order to test whether blocking the inflammatory response to exercise interferes with the neural and psychological effects of exercise.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Depression

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1, Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Session 1
Arm Type
Experimental
Arm Description
Exercise (30 min on bicycle ergometer at 60% peak power output) and a single oral dose 800mg of ibuprofen
Arm Title
Session 2
Arm Type
Active Comparator
Arm Description
Exercise (30 min on bicycle ergometer at 60% peak power output) and matching placebo
Arm Title
Session 3
Arm Type
Active Comparator
Arm Description
30 minutes rest (sitting in chair) and a single oral dose 800mg of ibuprofen
Arm Title
Session 4
Arm Type
Placebo Comparator
Arm Description
30 minutes rest (sitting in chair) and matching placebo
Intervention Type
Other
Intervention Name(s)
Exercise Session
Intervention Description
30 min cycling on bicycle ergometer at 60% peak power output
Intervention Type
Drug
Intervention Name(s)
Ibuprofen 800 mg
Intervention Description
A single oral dose of Ibuprofen
Intervention Type
Other
Intervention Name(s)
Rest
Intervention Description
Resting for 30 min in chair
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Matched placebo
Primary Outcome Measure Information:
Title
Depressive Symptoms
Description
Quick Inventory of Depressive Symptomatology (QIDS)
Time Frame
Difference between QIDS scores at baseline and two hours post intervention
Title
Inflammation
Description
Serum concentrations of interleukin 6 (IL-6)
Time Frame
Difference between IL-6 at baseline and two hours post intervention
Secondary Outcome Measure Information:
Title
Neural Response to Reward
Description
Percent Signal Change in Ventral Striatum During Monetary Incentive Delay (MID) task
Time Frame
One hour post intervention
Title
Brain Volume
Description
Gray Matter Volume of the Hippocampus
Time Frame
One hour post intervention
Title
Inflammation
Description
Serum concentrations of tumor necrosis factor (TNF)
Time Frame
Difference between TNF at baseline and two hours post intervention
Title
Inflammation
Description
Serum concentrations of interleukin 10 (IL-10)
Time Frame
Difference between IL-10 at baseline and two hours post intervention
Title
Depressive Symptoms
Description
Score on the Montgomery-Asberg Depression Rating Scale (MADRS)
Time Frame
Difference between MADRS scores at baseline and two hours post intervention
Title
Anhedonia
Description
Score on the Snaith-Hamilton Pleasure Scale (SHAPS)
Time Frame
Difference between SHAPS scores at baseline and two hours post intervention
Title
Anxiety
Description
Score on the Hamilton Anxiety Scale (Clinician-Administered Version - SIGH-A)
Time Frame
Difference between SIGH-A scores at baseline and two hours post intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Provision of signed and dated informed consent form Has an established residence and phone Agrees to and is eligible for behavioral testing, magnetic resonance imaging, and blood draws. Stated willingness to comply with all study procedures and lifestyle considerations (see Section 5.3, Lifestyle Considerations) and availability for the duration of the study Males and females; Age 18-55 years DSM-V diagnosis of bipolar disorder Has a current major depressive episode Depression at enrollment of sufficient severity to score > 11 on the QIDS Be stably medicated for at least 4 weeks (a non-medicated subject may be included in the study if judged to be appropriate in the medical/psychiatric opinion of the investigator) BMI between 18.5 and 35 Exclusion Criteria: Diagnosis of any other major psychiatric disorder such as schizoaffective disorder, schizophrenia, or current psychotic depression A history of bipolar disorder with rapid cycling Concurrent manic symptoms of sufficient severity to pose a substantial risk of the development of a manic episode (>19 on the YMRS) Current drug or alcohol or substance use disorder moderate or severe, except nicotine (within 6 months for severe use disorder; 2 months for moderate use disorder) Volunteers currently receiving more than 4 mood-relevant psychotropic medications in a daily regimen (since this may signify a more brittle or complex clinical state) Taking any of the following medications: medications with significant interactions with ibuprofen; immune-modulating medications (e.g. oral steroids); regular use of NSAIDs (> 3 times per week) Current or prior cardiac disease, cardiac arrhythmia (e.g. supraventricular tachycardia, atrial fibrillation, ventricular fibrillation), or history of cardiac ablation therapy Unstable medical condition, including significant respiratory disease (e.g., asthma, reactive airway disease (i.e., exercise induced asthma), or chronic obstructive pulmonary disease (COPD)), liver disease, hypothyroidism (i.e., condition not adequately stabilized for 3 months), or other conditions likely to require hospitalization or with a life expectancy of < 6 months (e.g., cancer). History of claustrophobia that would prevent participation in imaging scans Actively suicidal, as defined by expressive ideation with a plan and intent for suicide or developing suicidal ideation that requires immediate medical or treatment intervention or a suicide attempt within the previous six months Participants who endorse a history of moderate to severe traumatic brain injury (>30 min. loss of consciousness or >24 hours posttraumatic amnesia) or other neurocognitive disorder with evidence of neurological deficits Inadequate understanding of English Currently pregnant or breast-feeding; fecund women not using adequate contraceptive methods; plan to become pregnant within 12 months Metal in the body (e.g. history of working as a sheet metal worker) or pacemaker which is a contra-indication to magnetic resonance imaging Has epilepsy, a neuromuscular disorder, or tardive dyskinesia Has a chronic infectious illness Requires immediate hospitalization for psychiatric disorder Requires medications for a general medical condition that contraindicate any study medication Receiving or have received during the index episode vagus nerve stimulation, electroconvulsive therapy, transcranial magnetic stimulation, or other somatic treatments Allergy to, or other medical contraindication to ibuprofen (e.g. stomach ulcers) Symptoms of myalgic encephalomyelitis/chronic fatigue syndrome or "long-COVID". Current use of medications or dietary supplements for weight or appetite control, whether prescribed or not Ulcerative colitis, Crohn's disease or other autoimmune disorder (except treated hypothyroidism) Activity restrictions that limit the subject's ability to engage in intense physical activity Use of beta-blockers, calcium channel inhibitors, or other heart-modulating medications (e.g., amiodarone) Clinically significant abnormality on EKG Hypertension, hepatitis, renal dysfunction, and/or anemia of sufficient severity to pose a risk to the participant Moderate or heavy smoker based on Fagerstrom Resting heart rate >100 beats per minute, systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg Clinically significant screening laboratory abnormalities not covered above Any reason not listed herein that would make participation in the study hazardous
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jonathan Savitz
Phone
9185025104
Email
jsavitz@laureateinstitute.org
Facility Information:
Facility Name
Laureate Institute for Brain Research
City
Tulsa
State/Province
Oklahoma
ZIP/Postal Code
74136
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression

We'll reach out to this number within 24 hrs